Anti-helicobacter vaccine complex

ABSTRACT

A therapeutical vaccine complex having activity specific for Helicobacter bacteria as well as non-specific immunomodulation activity for regulating the natural defences of the body, is disclosed. The drug is also useful for preventing relapses, particularly in cases of resistance to conventional treatment. The drug essentially consists of RNA, selective membrane fractions of microbial germs, particular amino acid sequences, sodium chloride and a steroidal anti-inflammatory in predetermined proportions enabling simultaneous delivery of antibiotics and frenosecretories. Said drug is particularly suitable for treating digestive tract diseases caused by Helicobacter (antral gastritis, duodenal ulcers, gastric ulcers, oesophagitis, hepatitis) and preventing stomach cancer and degenerative infectious MALT (mucosa-associated lymphoid tissue) lymphoma, as well as coronary diseases directly or indirectly dependent on Helicobacter infections.

[0001] The present invention relates to a therapeutic and preventive anti-bacterial vaccine complex which possesses a vaccinating power linked to the presence of specific antigens against Helicobacter pylori (previously called Campylobacter pylori), Helicobacter hepaticus, Helicobacter coronari, and nonspecific antigens providing immunomodulation.

[0002] [MARSHALL B. J., WARREN Jr., Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration Lancet 1984: i:1311-4)].

[0003] [MÉGRAUD F., Helicobacter pylori, the most important bacterium among the mucus bacteria, La lettre de l'infectiologue 1993; 8 (suppl. 4): 151-9].

[0004] It is well known, in bacteriology, that the surface antigens of the walls, membranes or capsules (combined or free in soluble form in the culture medium) are of a glycoprotein, polypeptide or polysaccharide nature.

[0005] Vaccines combining associative factors, such as membrane proteoglycan or polysaccharide substances, extracted from pathogenic microbes, with ribonucleic acid of ribosomal origin (RNA) can be used in the production of acellular vaccines (cf. Inf. and Immunity, 1, 574-82, 1970 and PCT WO 94/22462).

[0006] These vaccines use specific antigens corresponding to specifically determined microbial diseases.

[0007] However, the antigenicity is essentially linked to the level of RNA (of the ribosomes in particular) in microbial cells, inter alia. Immunocompetent cells (ICC) directly use these RNAs as active carriers.

[0008] To produce the complex of the invention, with the Helicobacter bacterial serotype antigen, we coupled preferably by means of covalent bonds, RNA, preferably of ribosomal origin, with an amino acid sequence of glycoprotein nature, preferably present in type III collagen. In humans, collagen represents approximately a third of the proteins in the body. The type III was chosen for its amino acid sequence and its presence in the dermis, the vascular wall and the digestive epithelial mucous membranes.

[0009] In our complex, we have used, as stabilizer, cell membrane fractions derived from the same microbes as those which served for the production of the ribosomal RNA. These membrane fractions contain all of the peptidoglycan substances and are known, in addition, as immunity adjuvants.

[0010] It is, in addition to Helicobacter pylori, hepaticus and coronari, useful to have—glucopolysaccharide or proteoglycan—membrane fractions derived from various microbial organisms which have served to provide the RNA by extraction of their ribosomes, which microbes are known for their immunogenesis (recruitment of macrophages, activation of T lymphocytes, potentiation of the synthesis of immunoglobulins, secretory IgA's in particular (11 S), increase in phagocytosis and stimulation of dependent T cells and the like).

[0011] This was thus thought of because, in the precise case of the pathogenesis induced by Helicobacter pylori, hepaticus or helmannii, coronari, the body must produce, in addition to the specific humoral immune response, a cellular response in order to make up for the inefficacy of the antibodies in protecting the individual.

[0012] It is known that cell-mediated response does not give rise to the production of antibodies, but only to the generation of sensitized lymphoid cells specific for the antigen involved.

[0013] The T lymphocytes act by themselves and/or through the cytokines, and either an inflammatory type response or a cytotoxic response is observed.

[0014] The pathogenic power of Helicobacter lies in its ability to colonize the gastric mucous membrane, to survive in the gastric juice and to multiply therein in spite of the host's immune response, and to generate lesions which are sometimes irreversible (adenocarcinoma, gastric lymphoma or MALT “mucous associated lymphoid tissue” lymphomas),

[0015] [PARSONNET J: Helicobacter pylori and gastric cancer. Gastroenterol Clin North Am 1993, 22:89-104.

[0016] WORTHERSPOON A. C., DOGLIONI C., DISS T. C. et al.: Regression of primary low-grade B-cell gastric lymphoma of mucosa associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet 1993; 342:575-7.

[0017] MOHANDAS, Helicobacter pylori and lymphoma, N Eng J Med 1994: 331:746-7].

[0018] when it is insufficient during injection: resistance to phagocytosis, induction of apoptosis and the like.

[0019] [PETERSON P. K., VERHOEF J., SCHMELING D. & QUIE P. G.: Kinetics of phagocytosis and bacterial killing by human polymorphonuclear leucocytes and monocytes, J. Infec. Dis. 136:502-509, 1977.

[0020] KIEHLBAUCH J. A., ALBACH R. A., BAUM I. K., CHANG K. P. Phagocytosis of Campylobacter jejuni and its intracellular survival in mononuclear phagocytes, Infect Immun 1985; 48:446-51].

Constituents of the Vaccine Complex Which is the Subject of the Invention

[0021] The complex of the invention comprises dual molecules constituted by the coupling of a functional amino acid arm, ensuring binding to a target, with a genetic RNA arm corresponding to the coded description of the composition of the functional arm.

[0022] A—The RNAs of ribosomal origin which can be used may be extracted from the strains chosen from the following group, this list not being limitative:

[0023]Helicobacter pylori (or Campylobacter), hepaticus, coronari . . .

[0024]Klebsiella pneumoniae

[0025] Streptococcus (pneumoniae and pyrogenes)

[0026]Staphilococcus aureus

[0027]Serratia marcescens

[0028]Escherichia coli

[0029]Salmonella typhimurium

[0030] Corynebacterium (granulosum, parvum, acnes)

[0031] Mycobacterium (tuberculosis, smegmatis, chelonei)

[0032]Hemophilus influenzae

[0033] Pneumococcus type II

[0034]Rothia dentocariosus

[0035]Bacterium coli

[0036]Shigella dysentariae

[0037] Enterococcus

[0038] Nocardia (asteroides, brasiliensis, rhodocrans, opaca, rubra)

[0039]Calmette-Guerin bacillus,

[0040] or from a mixture thereof.

[0041] The average molecular weights of these RNAs are between 5104 and 108 Dalton.

[0042] Many industrial processes exist for the preparation of RNA. We will cite as an example the process for extracting RNA described in Infect. and Immunity, 1. 574-82. 1970; the bacteria are ground and then subjected to fractional precipitation, the ribosomal proteins are solubilized, the RNA precipitated is treated with Pronase and, finally, purified by ion-exchange chromatography.

[0043] If the RNA is obtained by enzymatic route, the final purification may be carried out by molecular sieve chromatography. See in particular on this subject:

[0044] C. EHRESMAN (1972)—Biochimie, 54, 901

[0045] H. KAGAWA (1972)—J. Biochem., (1972), 827

[0046] M. SANTER (1973)—J. Bact., 116, 1304

[0047] NOMURA (1974)—Ribosomes—Ed. Cold Spring Harbor Laboratory.

[0048] B—The membrane fractions of bacterial cells which can be used may be extracted from the following strains, the lists given not being limitative:

[0049] 1—For Capsular Polysaccharides

[0050] a. Helicobacter pylori and hepaticus

[0051] b. Klebsiella pneumoniae

[0052] c. Streptococcus pneumoniae

[0053] d. Hemophilus influenzae

[0054] e. Escherichia coli

[0055] a. Helicobacter pylori, hepaticus and coronari

[0056] [HILLS B. A., Gastric mucosal barrier: evidence for Helicobacter pylori ingesting gastric surfactant and deriving protection from it. Gut. 1993 May: 34(5): 588-93.

[0057] GENTA R. M., ROBASON G O, GRAHAM D. Y., Simultaneous visualization of Helicobacter pylori and gastric morphology; a new strain. Human Pathology; 1994 Mar: 25 (3); 221-6.

[0058] MAJEWSKI S. I., and C. S. GOODWIN, 1988, Restriction endonuclease analysis of the genome of Campylobacter pylori with a rapid extraction method: evidence for considerable genomic variation. J. Infect. Dis. 157; 465-471.

[0059] GEIS G., LEYING H., SUERBAUM S., MAI U. & OPFERKUCH W.: Ultrastructure and chemical analysis of Campylobacter pylori flagella. J. Clin. Microbiol, 27; 436-441, 1989].

[0060] b. Klebsiella pneumoniae

[0061] [C. ERBING, L. KENNE, B. LINBERG, J. LONNGREN (1976)—Structural studies of the capsular polysaccharide of Klebsiella pneumoniae type I (Carbohydr. Res., 50 (1976) 115-20).

[0062] W. NIMMICH (1968) Zur Isolierung und qualitativen Bausteinanalyse der K. Antigen von Klebsiellen [Isolation of the Klebsiella K antigen and qualitative analysis of its structural components] (Med. Mikrobio and Immunol., 154, 117, 131).

[0063] C. RICHARD (1973)—Etude antigenique et biochimique de 500 souches de Klebsiella [Antigenic and biochemical study of 500 Klebsiella strains] (Ann. Biol. Clin., 1973)].

[0064] c. Streptococcus pneumoniae

[0065] [F. KAUFFMANN and E. LUND (1954) (Int. Bull. Bact. Nomencl. 4, 125-28).

[0066] FELTON and OTTINGER (J. of Bacteriology, 1942, 43, 94, 105)

[0067] M. COLIN, M. D. MAC LEOD et al., Prevention of pneumococcal pneumoniae by immunization with specific capsular polysaccharides (J. Exp. Med, 1945, 82, 445-65).

[0068] A. R. DOCHEZ and O. T. AVERY—The elaboration of specific soluble substance by Pneumococcus during growth (1971) (J. Exp. Med. 26, 477-93).

[0069] WEST PHAL and LUDERITZ (1952) (Z. Naturf. 7B, 148).

[0070] C. P. J. GLAUDEMANS and H. P. TREFFERS—An improved preparation of the capsular polysaccharide from Diplococcus pneumoniae (Carbohydr. Res. 1967, 4, 181-84)].

[0071] d. Hemophilus influenzae (capsular polysaccharide polyribosephosphate type)

[0072] [P. ANDERSON et al. (1972)—Immunization of humans with polyribosephosphate, the capsular antigen of Hemophilus influenzae type B (J. of Clin. Invest., vol. 51, 1972, 39-44).

[0073] P. ANDERSON et al. (1977)—Isolation of the capsular polysaccharide from supernatant of Hemophilus influenzae type B (Infect. and Immun., 1977, 15 (2), 472-77)].

[0074] e. Escherichia coli (capsular polysaccharides)

[0075] [LUDERITZ et al. (1977)—Somatic and capsular antigens of gram-negative bacteria (Compr. Biochem. 26 A, 105-228).

[0076] BOYER H. W. and D. ROULLAND-DISSOIX, (1969)—A complementation analysis of the restriction and modification in Escherichia coli, J. Mol. Biol. (41:459-472).

[0077] CASADABAN, M. and S. N. COHEN (1980)—Analysis of gene control signals by DNA fusion and cloning in E. coli, J. Mol. Biol. (138; 179-207).

[0078] LUGTENBERG B., J. Meijers, R. Peters, P van der Hock and L. van Alphen (1975)—Electrophoretic resolution of the “major outer membrane protein” of Escherichia coli K12 into four bands. (FEBS Lett. 58; 254-258)].

[0079] 2—For the Membrane Lipopolysaccharides (LPS)

[0080] Corynebacterium (avidum, bovis, diphteriae, enzymicum, equi, fascians, flaccum, faciens, flavidum, fustiforme, granulosum, helvolum, hypertrophicans, insidiosum, liquefaciens, parvum, paurometabolum, pyogenes, tumescens, xerosis)

[0081] and the gram-negatives:

[0082]Helicobacter pylori, hepaticus, coronari

[0083] Klebsiella (pneumoniae and rhinoscleromatis)

[0084]Salmonella typhimurium

[0085] Serratia (marcescens, corralina, indica, plymuthica, kiluea)

[0086]Neisseria meningitidis

[0087]Escherichia coli

[0088] [GOODWIN C. S. “Helicobacter Pylori: 10th anniversary of its culture in April 1982”. (Gut 1993; 34: 293-4).

[0089] C. ERBIN et al. (1977)—Structural studies on the Klebsiella LPS (Carbohydr. Res., 56, 377-81).

[0090] C. B. CASTOR et al. (1971)—Characteristics of a highly purified pyrogenic LPS of Klebsiella pneumoniae (J. of Pharm. Sci. 60, (10), 1578-80).

[0091] K. FUKUSHI (1964)—Extraction and purification of endotoxin from Enterobacteriaceae: a comparison of selected methods and sources (J. of Bacteriol. 87, (2), 391-400).

[0092] G. A. LIMJUCO—Studies on the chemical composition of LPS from Neisseria meningitidis group B (J. of Gen. Microbiol. 1978, 104, 187-91).

[0093] G. A. ADAMS (1967)—Extraction of LPS from gram-negative bacteria with DMSO (Canad. J. Biochem., 45, 422-26).

[0094] K. G. JOHNSON (1976)—Improved techniques for the preparation of bacterial LPS (Canad. J. Microbiol. (22), 29-34).

[0095] Y. B. KIM et al. (1967)—Biologically active endotoxins from Salmonella mutans (J. of Bacteriol., 94, (5), 1320-261)].

[0096] 3—For the Membrane Proteins

[0097]Helicobacter pylori

[0098]Escherichia coli

[0099]Serratia marcescens

[0100]Streptococcus pyogenes

[0101]Salmonella typhimurium.

[0102]Helicobacter pylori, Hepaticus, coronari

[0103] GOBERT (B.), LABIGNE (A.), de KORWIN (J. D.), CONROY (M. C.), BENE (M. C.), FAURE (G. C.)—Polymerase chain reaction for Helicobacter pylori, (Rev. Esp. Enf Digest, 1980, 78 (suppl 1), 4.

[0104] TOWBIN, H., T. STAEHELIN and J. GORDON, 1979. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets; procedure and some applications. Proc. Natl. Acad. Sci. USA 76:4350-4354.

[0105]Escherichia coli

[0106] S. F. STIRM et al. (1967)—Episome, carried surface antigen K 88 of Escherichia coli (J. of Bactgeriol., 93, (2), 731-39).

[0107] S. J. BETZ et al. (1977)—Chemical and biological properties of a protein rich fraction of bacterial LPS (J. of Immunol., 119 (4), 1475-81).

[0108]Serratia marcescens

[0109] W. WOBER (1971)—Studies on the protein moiety of endotoxin from gram-negative bacteria, characterisation of the protein-moiety isolated by acetic acid hydrolysis of endotoxin of Serratia marcescens.

[0110]Streptococcus pyrogenes

[0111] M. K. WITTNER (1977)—Homologous and heterologous protection of mice with group-A Streptococcal M protein vaccine (Infect. and Immun., 1977, 15, (1), 104-8).

[0112]Salmonella thyphimurium

[0113] N. KUUSI et al. (1979)—Immunization with major outer mebrane protein in experimental salmonellosis of mice (Infect. and Immun., 1979, 25, (3), 857-62).

[0114] C. BARBER et al. (1972)—The protective role of proteins from Salmonella thyphimurium in infection of mice with their natural pathogen (Rev. Immunol., 36, 77-81).

[0115] G. DELORD (1979)—Etude d'un antigène vaccinant contenu dans le surnageant de culture de Salmonella thyphimurium, souche M-206. [Study of a vaccinating antigen contained in the culture supernatant of Salmonella thyphimurium strain M-206] Medical thesis in Lyon No. 428, 1979.

[0116] G. W. GOODMAN (1979)—Characterization of the chemical and physical properties of a novel B-lymphocyte activator endotoxin protein (Infect. and Immun., 1979, 24(3), 685-96).

[0117] 4—For the Teichoic and Lipoteichoic Acids

[0118] Streptococci, staphylococci and lactobacilli (the surface of gram-positive bacteria is made of teichoic acid, which is a glycerol polymer, linked by phosphodiester bridges).

[0119] The following articles describe the methods of production:

[0120] M. M. BURGER (1966)—Teichoic acids: antigenic determinants, chain separation and their location in the cell wall (Microbiology 56, 910-17).

[0121] K. W. KNOX (1973)—Immunological properties of teichoic acids (Bacteriol. Reviews, 37, 21, 215-57).

[0122] G. A. MILLER (1976)—Effects of streptococcal lipoteichoic acid on host response in mice (Infect. and Immun., 1976, 13, (5), 1408-17).

[0123] A. J. WICKEN et al. (1975)—Lipoteichoic acids: a new class of bacterial antigens (Science, 187, 1161-67).

Various Assays Possible

[0124] RNA

[0125] FISKE and SUBBAROW—Assay of phosphorus. HPLC chromatography on an ion-exchange column for qualitative control (J. Biol. Chem. (1926), 66, 375).

[0126] Proteins

[0127] LOWRY (J. Biol. Chem. (1951), 193, 265-75).

[0128] Hexoses

[0129] T. A. SCOTT—Colorimetric assay using anthrone (Anal. Chem. (1953). 25, 1956-61).

[0130] Hexosamines

[0131] L. A. ELSON (Biochem. J (1953), 27, 1824-28).

[0132] Lipopolysaccharides

[0133] J. JANDA and E. WORK (Febs Letters, 1971, 16(4) , 343-45).

[0134] C—The other immunity adjuvant factors, in addition to the membrane fractions, are

[0135] collagen type III

[0136] sodium chloride

[0137] The collagen type III used is characterized by: a - Amino acid sequences similar to the following sequence (the concentrations are expressed in g/kg): aspartic acid AA 51.5 hydroxyproline HP 107.0 threonine TH 16.1 serine SE 27.8 glutamic acid GA 95.9 proline PR 124.0 glycine GL 149.0 alanine AL 87.9 valine VA 23.3 methionine ME 7.5 isoleucine IL 14.4 leucine LE 27.8 tyrosine TY 6.7 phenylaline PA 14.4 lysine LY 28.6 histidine HI 5.5 arginine AR 73.0 b - The following standard analysis: colour yellowish white apparent density 250 g/l moisture 6% pH of a 10% solution 6.9 Engler viscosity at 40° C. 2.5 (17.75% solution) fat content 0.9% ash content 2.2% content of Fe + Cu + Ca 462 mg/kg heavy metals not detectable by arc emission spectrography elemental analysis C 46.80% H  7.10% N 14.96%

[0138] The composition of the vaccine complex which is the subject of the invention, combining ribosomal RNAs or RNA fragments, membrane fractions (for example proteoglycans from Klebsiella pneumoniae) and collagen type III, supplemented with sodium chloride and an anti-inflammatory agent, makes it possible, by administration of low doses causing no toxicity, to obtain a high level of protection and of cure.

[0139] The preferred presentation is the injectable form of the composition presented above, but it is possible to use other presentations and/or other areas or additives compatible with a medical use.

Mechanism of Action of the Vaccine Complex

[0140] This therapeutic (vaccine) complex may be assimilated to a specific vaccine (through an “inert system” which is intended to increase the immunogenicity of a recombinant subunit vaccine and of vaccines consisting of peptides), and a nonspecific vaccine with the characteristics of a lymphokine, which, by attaching to the macrophages, plays an essential role in the immune response towards Helicobacter [KAZI J. I., SINNIAH R., JAFFRAY N. A., ALAM S. M., ZAMAN V., ZUBERI S. J. & KAZI A. M.: Cellular and humoral immune response in Campylobacter pylori-associated chronic gastritis, J. Pathol. 159; 231-237, 1989].

[0141] Since 1974-75 (A. S. and G. P. YOUMANS), it has been observed that the effect of inhibition of the immune response to RNA was provided by various inhibitors.

[0142] YOUMANS had worked on a single bacterial strain (Mycobacterium tuberculosis), whose “parasitism” is solely intracellular.

[0143] VENNEMAN et al. have thought since 1972 that the real antigen could be associated with RNA, whose role could be that of an adjuvant. They vaccinated mice with ribosomal RNA, extracted with phenol at 65° C. from ribosomes of a strain of Salmonella typhimurium. Thirty days after this vaccination, it was found that the animals were better protected than with an (attenuated) live strain vaccine.

[0144] It was in particular observed that the level of protection depended on the quantity of RNA injected.

[0145] For example: the ribosomal RNA extracted from Streptococcus pneumoniae induces protection of a humoral nature and the ribosomal RNA extracted from Klebsiella pneumoniae induces protection of a cellular nature.

[0146] [TRIEU-CUOT, P., G. GERBAUD, T. LAMBERT and P. COURVALIN (1985)—In vivo transfer of genetic information between gram-positive and gram-negative bacteria. (EMBO J. 4:3583-3587)].

[0147] This mixture, when injected in vivo into mice and guinea pigs, exerts an action on the alveolar macrophages.

[0148] This “transient” effect is determined by assaying the acid phosphatase in the direct haemolysis plaques in contact with mouse spleen cells.

[0149] The treatment with our therapeutic and vaccine complex is, for its part, followed by a cellular and humoral immunostimulant effect, with a significant specific and nonspecific action on Helicobacter pylori. It is the patient's own body which is stirred into action to “reject the infected cells”. A cure is obtained by the action of the PMNs (Polymorphonuclear leukocytes) and of the moncytes simultaneously stirred into action.

[0150] [ANDERSEN L. P.; NIELSEN H. Survival and ultrastructural changes of Helicobacter pylori after phagocytosis by human polymorphonuclear leukocytes and monocytes, APMIS; 1993 Jan.: 101(1); 61-72]

[0151] [STEIGBIGEL R. T., LAMBERT L. H. & REMINGTON J. S.; Phagocytic and bactericidal properties of normal human monocytes, J. Clim. Invest. 53; 131-142, 1974]

[0152] [YAM L. T., Li C. Y. & CROSBY W. H.; Cytochemical identification of monocytes and granulocytes, Am. J. Clin. Pathol. 55; 283-290, 1971].

[0153] This therapeutic mechanism therefore makes it possible to produce a natural cloning by virtue of the (nonspecific bacterial ribosomal) RNAs opsonized by the adjuvant developed (combination of membrane proteoglycans, of collagen type III and of sodium chloride).

[0154] This cloning induces vaccination against the idiotypes of the antibodies, as well as the production of antibodies against the site for attachment of the bacteria. To reduce or inhibit the inflammatory reaction, it is necessary to use, during treatments with the vaccine complex, corticoids (Betamethasone type, for example) in the form of disodium phosphate, at a dose of 20 to 60 mg, by the I.V. or I.M. route.

[0155] This action is also accompanied by production of endogenous interferon as well as an activation of the NK cells.

[0156] The aim of our immunomodulatory vaccine complex is therefore to induce a local and general immune response which has the effect of preventing or at least of reducing (down to a possible self-defence threshold) the proliferation of an infectious agent introduced into the body.

[0157] PRUUL H., LEE P. C., GOODWIN C. S. & MACDONALD P. J.—Interaction of Campylobacter pyloridis with human immune defence mechanisms, (J. Med. Microbiol. 23; 233-238, 1987).

[0158] RATHBONE B. J., WYATT J. I., WORSLEY B. W., SHIRES S. E., TREJDOSIEWICZ L. K., HEATLEY R. V. & LOSOWSKY M. S.—Systemic and local antibody response to gastric Campylobacter pyloridis in non-ulcer dyspepsia, (Gut. 27; 642-647, 1986).

[0159] STACEY A. R., HAWTIN P. R. & NEWELL D. G. -Local immune responses to Helicobacter pylori injections. In: Malgertheimer P. & Ditschuneit H. (Eds.): Helicobacter pylori, Gastritis and Peptic Ulcer, (Springer Verlag, Berlin-Heidelberg, 1990, pp. 162-166).

[0160] Our therapeutic innovation consists, inter alia, in moderating or eliminating the existence of “suppressive cells” exerting a proinfectious action, in causing an anti-ulcerous reaction by a defensive cellular and/or humoral response; it is the therapeutic response to the problem detected since 1993 by Kist et al.

[0161] [KIST M; SPIEGELHALDER C.; MORIKI T.; SCHAEFER H. E.—Interaction of Helicobacter pylori (strain 151) and Campylobacter coli with human peripheral polymorphonuclear granulocytes], and in preventing infectious recidivations:

[0162] BORODY T., ANDREWS P., MANCUSO N., JANKIEWICZ E., BRANDL S.—Helicobacter pylori reinfection 4 years post-eradication; (Lancet 1992, 339-1295).

[0163] BELL G. D., POWELL K. U., BURRIDGE S. M., HARRISON G., RAMEH B., WEIL J. et al.—Reinfection or recudescence after apparently successful eradication of Helicobacter pylori infection: Implications for treatment of patients with duodenal ulcer disease, (Q.J. Med 1993, 86; 375-382).

[0164] In conclusion, our therapeutic complex acts by directed evolution, producing RNA molecules which block the Helicobacter pylori infection and increase the immunodefence.

[0165] [SUERBAUM S., C. JOSENHANS, and A. LABIGNE (1993)—Cloning and genetic characterization of the Helicobacter pylori and Helicobacter mustelae flaB flagellin genes and construction of H. pylori flaA- and flaB-negative mutants by electroporation-mediated allelic exchange. (J. Bacteriol. 175:3278-3288).

[0166] HAAS R., T. F. MEYER, and J. P. VAN PUTTEN (1993)—Aflagellated mutants of Helicobacter pylori generated by genetic transformation of naturally competent strains using transposon shuttle mutagenesis. (Mol. Microbiol. 8:753-760)

[0167] CHEN M., LEE A., HAZELL S., HU P., LI Y.—Protective immunisation against Helicobacter: the need for stimulation of common mucosal immune system (abstract). (Gastroenterology 1993, 104 (suppl): A681)].

[0168] It was, moreover, observed during the various clinical trials which were carried out, that the complex of the invention could be successfully substituted for conventional treatments, using in particular triple therapy, in notorious cases of bacterial resistance.

Techniques for Administering the Vaccine Complex

[0169] The vaccine complex may be administered orally or parenterally:

[0170] either by direct intravenous injection

[0171] or by slow infusion

[0172] or by subcutaneous injection

[0173] or by the transdermal route (per 24 h)

[0174] These various techniques have been tried successfully.

[0175] The daily doses and their frequency depend largely on the patient's condition. There is no risk of an overdose given the non-toxicity of the complex.

[0176] By the intravenous route sequences of one week per month may be used, each day of the week of treatment comprising a slow infusion of 500 ml of a solution containing:

[0177] 0.9% sodium chloride

[0178] 40 μg of membrane saccharide fractions (Klebsiella pneumoniae proteoglycans)

[0179] 30 μg of (ribosomal) RNA from: * Helicobacter pylori 7 μg * Diplococcus pneumoniae 7 μg * Streptococcus pyogenes (A 12) 7 μg * Klebsiella pneumoniae 7 μg * Hemophilus influenzae 2 μg

[0180] 10 μg of collagen type III described above

[0181] 8 mg of Betamethasone disodium phosphate (that is to say 2 ml of injectable solution).

[0182] This treatment by slow I.V. infusion may be replaced by a treatment by subcutaneous injections on patients who can be followed on an ambulatory basis, each injection containing:

[0183] 40 μg of membrane saccharide fractions (Klebsiella pneumoniae proteoglycans)

[0184] 30 μg of (ribosomal) RNA from: * Helicobacter pylori 7 μg * Diplococcus pneumoniae 7 μg * Streptococcus pyogenes (A 12) 7 μg * Klebsiella pneumoniae 7 μg * Hemophilus influenzae 2 μg

[0185] 10 μg of collagen type III described above

[0186] 0.5 ml of sodium chloride at 0.9%

[0187] 4 mg of Betamethasone disodium phosphate (that is to say 1 ml of injectable solution).

[0188] This treatment may be continued for several weeks.

[0189] By the oral route:

[0190] using tablets,

[0191] 2 tablets per day, in a single dose in the morning on an empty stomach, each tablet containing:

[0192] 400 μg of membrane saccharide fractions (Klebsiella pneumoniae proteoglycans)

[0193] 300 μg of (ribosomal) RNA from: * Helicobacter pylori 70 μg * Diplococcus pneumoniae 70 μg * Streptococcus pyogenes (A 12) 70 μg * Klebsiella pneumoniae 70 μg * Hemophilus influenzae 20 μg

[0194] 100 μg of collagen type III described above

[0195] 2 mg of Betamethasone disodium phosphate.

[0196] This treatment can be provided at the rate of 2 tablets per day for one month, followed by booster periods of two tablets per day, one week per month for 3 months.

[0197] By the transdermal route

[0198] Adhesive transdermal therapeutic sytem composed of a reservoir and a permeable membrane providing continuous passage of the active ingredients across the skin and into the bloodstream at a constant rate.

[0199] The device should be stuck to a healthy skin surface which is dry and not very hairy (side wall of the abdomen or of the thorax for example).

[0200] It comprises:

[0201] adhesive polymer

[0202] carrier for the adhesive: polyethylene

[0203] silicone polyester protective filter

[0204] Its content is the content of one tablet, and its dosage is identical to the oral route (at the rate of one “patch” for 2 daily tablets).

[0205] The following non-limiting examples are given to illustrate the concrete results for our therapeutic vaccine complex.

EXAMPLE 1

[0206] Mr. Robert G., 64 years old, was hospitalized following epigastralgia, pyrosis and abdominal pain associated with a transit disorder with alternating diarrhoea—constipation. Digestive endoscopy showed a gastrooesophageal reflux pathology by the opening of the cardia, causing an oesophagitis and a peptic ulcer of the lower oesophagus.

[0207] Biopsies were performed, as well as a rapid urease test. The latter, as well as anatomopathology and culture, confirmed the presence of Helicobacter pylori.

[0208] Conventional treatment (antisecretory and two antibiotics) was prescribed. The tritherapy did not lead to a clinical cure.

[0209] Six weeks after the end of the treatment, verification of eradication by the ¹³C-labelled urea breath test led to conclusion on the proliferation of bacteria because of its positive nature.

[0210] The treatment with the vaccine complex which is the subject of the invention was then carried out in the form of subcutaneous injections.

[0211] A month later, clinical cure was observed and the carbon-13-labelled urea breath test was negative.

[0212] Six months later, another verification by the ¹³C-labelled urea breath test and a verification endoscopy showed an established cure.

[0213] For one year, the cure has been definitive.

EXAMPLE 2

[0214] Mr. Serge Y., 48 years old, had a type B antral gastritis. Treatment with immunomodulatory complex (the only previous treatments were gastric dressings) in IV form. Clinical cure was obtained fifteen days after the therapeutic sequence. The verifications (¹³C-labelled urea breath test) have been negative for one year.

EXAMPLE 3

[0215] Mr. Pierre K. had a duodenal ulcer confirmed by endoscopy (+biopsy, urease test, ELISA tests).

[0216] Treatment by the oral route was then introduced. Three weeks later, clinical cure was obtained.

[0217] Six weeks later, verification by the ¹³C-labelled urea breath test confirmed the eradication.

[0218] Six months later, no recidivation was recorded, and the Elisa test showed a nonsignificant (<50%) antibody level.

EXAMPLE 4

[0219] Mrs. Sarah L. had a duodenal ulcer associated with a type B gastritis.

[0220] The presence of gastric cancer was detected among her brothers and sisters. A full check-up was carried out to show the positive nature of all the tests by an invasive method: culture, histology, amplification of the viral genome (PCR), urea test.

[0221] Treatment by the intravenous route over one week and then by subcutaneous boosters over six months was then introduced.

[0222] Given the high familial risk, an endoscopy with biopsy was performed from the third month: PCR, cytology, culture, CLO test, were negative.

[0223] At the sixth month, a breath test (¹³C) confirmed clinical cure. 

1. Specific therapeutic immunomodulatory complex, characterized in that it comprises: dual molecules constituted by the coupling of a functional amino acid arm, ensuring binding to a target, with a genetic RNA arm corresponding to the coded description of the composition of the functional arm, bacterial membrane fractions glycopeptides and/or lipopolysaccharides, the ribonucleic acids (RNA) being of ribosomal origin and extracted from strains chosen from the following group: Helicobacter pylori, hepaticus, coronari, campylobacter or from a mixture thereof.
 2. Immunomodulatory complex according to claim 1, characterized in that the amino acids are amino acids from collagen.
 3. Immunomodulatory complex according to claim 2, characterized in that the amino acids from collagen are chosen from the following group: aspartic acid, hydroxyproline, threonine, serine, glutamic acid, proline, glycine, alanine, valine, methionine, isoleucine, leucine, tyrosine, phenylaline, lysine, histidine, arginine, or a mixture thereof.
 4. Immunomodulatory complex according to one of claims 1 to 3, for its use in the treatment of diseases caused by Helicobacter bacteria, by the production of antibodies and the production of endogenous interferon.
 5. Immunomodulatory complex according to one of claims 1 to 3, for its use as an anti-idiotype vaccine against the idiotypes of anti-bacterial antibodies which make it possible to avoid, in particular, recidivations of the initial digestive tract pathology.
 6. Immunomodulatory complex according to one of claims 1 to 3, for its use against bacterial resistance to conventional antibiotic treatments and the like.
 7. Anti-Helicobacter-specific immunomodulatory and vaccine complex according to one of the preceding claims, characterized in that it is presented in a packaging allowing the simultaneous administration of major anti-inflammatory agents of the corticoid type, of antibiotics, of antisecretory agents, (proton pump inhibitors, of the type including Omeprazole or anti-H2, and the like) or other products with bacteriostatic, bactericidal or bacteriolytic effects, for eradicating Helicobacter generating pathogeneses by factors linked to the bacterium (production of various cytotoxins, of inflammation mediators: Interleukin I, tumour necrosis factor alpha), or by factors linked to the host.
 8. Immunomodulatory complex according to the preceding claim, characterized by a packaging in the form such that it can be administered by various routes: infusions, intravenous injections, subcutaneous injections, transdermal devices, or per os. 